News

ModifyHealth Announces Strategic, Series B Investment from Middleland Capital’s VTC Ventures to Support Increased Demand for its Food-as-Medicine Solutions

ModifyHealth™, an innovative food-as-medicine platform and provider of medically tailored meals, welcomes VTC Ventures as a strategic addition to its Series B investment led by RC Capital and Nashville Capital Network. The funding will support ModifyHealth’s continued growth of its category-leading food-as-medicine solutions and further expansion of its nationwide operations to deliver meaningful patient outcomes.

Middleland Capital is a member of the investment syndicate that recently launched the Food, Nutrition and Health Investor Coalition (FNHIC), which will drive $2.5 billion in private investment over the next three years to improve hunger and health outcomes through food. The coalition plans to highlight and financially support the incredible amount of emerging technological innovation underway that leverages the power of affordable and nutritious food to remediate hunger and improve human health.

Working directly with patients and partnering with payors, employers, and healthcare systems, ModifyHealth’s turnkey FIT™ (Foundation, Immersion, Transition) program decreases cost and improves outcomes for chronic conditions like type 2 diabetes, hypertension, kidney disease, obesity, and irritable bowel syndrome, where dietary management is a recommended treatment.

“Evidence supports what all of us intuitively know – healthy diets and lifestyles are central to preventing, managing, and, in many cases, reversing chronic conditions,” says ModifyHealth Founder & CEO G.B. Pratt. “For many with chronic conditions, the ‘want to’ for a healthier lifestyle exists. It’s the ‘how to’ that remains a challenge. Our program is designed to make the ‘how to’ simple, achievable, and sustainable. We’re excited to partner with VTC Ventures and look forward to impacting lives together.”

“Partnering with high-growth, high-impact companies that deliver enduring value to the healthcare industry and, ultimately, better health outcomes for patients are central to our values,” said James Ramey, JD, Managing Director at VTC Ventures. “ModifyHealth’s team has delivered rapid growth nationally, and we look forward to supporting the company’s mission with this investment.” As part of the VTC Ventures investment, Carilion Clinic – a non-profit healthcare system serving one million people in Virginia’s Blue Ridge and Southwest Virginia – will explore using the ModifyHealth platform in patient care. “The VTC Ventures investment aligns with Carilion’s commitment to including lifestyle medicine as a foundation of healthy outcomes,” said Michael Jeremiah, MD, FAAFP, Chair of Family & Community Medicine and Senior Medical Director of Population Health at Carilion. “Our clinical team is excited about the potential of this platform to support our patients and value-based care initiatives in the communities we serve.”

Recent News

01/29/2026

NIRSense, Inc. & Aspen Medical USA (AMUSA): Strengthening Frontline Medicine: U.S.–Developed Tissue Oxygenation Technology Delivered to Ukraine

NIRSense and Aspen Medical USA (AMUSA) are pleased to announce the donation of 12 portable tissue-ischemia monitoring kits (comprising advanced sensor consoles plus tablets) to the Ministry of Defence of Ukraine (MoD) for deployment in frontline Role-1 and Role-2 casualty care facilities in Ukraine. These investigational prototype systems are provided for use by military medical

01/28/2026

Call for Judges for Science Fair

Each year, Virginia Bio recruits volunteer judges from the membership to attend the Virginia State Science and Engineering Fair to select the top three winners in the field of biosciences. The time commitment is limited to a pre-event online review of the submissions to select the finalists and then a few hours onsite at the

01/28/2026

University of Virginia Signs Master Research Collaboration Agreement with AstraZeneca to Accelerate Pre-Clinical Innovation

The University of Virginia (UVA) today announced the signing of a Master Research Collaboration Agreement with AstraZeneca designed to expedite pre-clinical research partnerships between the global biopharmaceutical company and UVA’s schools and departments. The agreement streamlines processes and enables AstraZeneca’s research and development teams to work more effectively and efficiently across UVA’s breadth of scientific